BACKGROUND: Aromatase inhibitor (AI) therapy is being extensively used as postoperative adjuvant therapy in patients with hormone receptor-positive postmenopausal breast cancer. On the other hand, it has been reported that ovarian function was restored when AI was administered to patients who had undergone chemical menopause with chemotherapy or tamoxifen. However, there have been no reports of comprehensive monitoring of estradiol (E2) in breast cancer patients with ordinary menopause who were being administered AI. PATIENTS AND METHODS: Beginning in March 2008, regular monitoring of the serum levels of E2, luteinizing hormone (LH) and follicle-stimulating hormone (FSH) was performed for 66 postmenopausal breast cancer patients who had been started on AI therapy. For this study, we chose anastrozole as the AI. The assays of those hormones were outsourced to a commercial clinical laboratory. RESULTS: In 4 of the 66 patients the serum E2 level was decreased at 3 months but had then increased at 6 months, while in 2 other patients E2 was decreased at both 3 and 6 months but had increased at 9 months. CONCLUSION: The results indicate that, in some breast cancer patients with ordinary menopause, E2 rebounds following AI therapy. In the future, E2 monitoring should be performed for a larger number of patients being administered AI therapy. TRIAL REGISTRATION: Our trial registration number is 19-11-1211.
BACKGROUND:Aromatase inhibitor (AI) therapy is being extensively used as postoperative adjuvant therapy in patients with hormone receptor-positive postmenopausal breast cancer. On the other hand, it has been reported that ovarian function was restored when AI was administered to patients who had undergone chemical menopause with chemotherapy or tamoxifen. However, there have been no reports of comprehensive monitoring of estradiol (E2) in breast cancerpatients with ordinary menopause who were being administered AI. PATIENTS AND METHODS: Beginning in March 2008, regular monitoring of the serum levels of E2, luteinizing hormone (LH) and follicle-stimulating hormone (FSH) was performed for 66 postmenopausal breast cancerpatients who had been started on AI therapy. For this study, we chose anastrozole as the AI. The assays of those hormones were outsourced to a commercial clinical laboratory. RESULTS: In 4 of the 66 patients the serum E2 level was decreased at 3 months but had then increased at 6 months, while in 2 other patients E2 was decreased at both 3 and 6 months but had increased at 9 months. CONCLUSION: The results indicate that, in some breast cancerpatients with ordinary menopause, E2 rebounds following AI therapy. In the future, E2 monitoring should be performed for a larger number of patients being administered AI therapy. TRIAL REGISTRATION: Our trial registration number is 19-11-1211.
Authors: J Geisler; S Detre; H Berntsen; L Ottestad; B Lindtjørn; M Dowsett; P Einstein Lønning Journal: Clin Cancer Res Date: 2001-05 Impact factor: 12.531
Authors: Ian E Smith; Mitch Dowsett; Yoon-Sim Yap; Geraldine Walsh; Per E Lønning; Richard J Santen; Daniel Hayes Journal: J Clin Oncol Date: 2006-06-01 Impact factor: 44.544
Authors: Harold J Burstein; Erica Mayer; Ann H Patridge; Holly O'Kane; Georgia Litsas; Steven E Come; Clifford A Hudis; Donald F Goldstein; Hyman B Muss; Eric P Winter; Judy E Garber Journal: Clin Breast Cancer Date: 2006-06 Impact factor: 3.225
Authors: Raimund Jakesz; Walter Jonat; Michael Gnant; Martina Mittlboeck; Richard Greil; Christoph Tausch; Joern Hilfrich; Werner Kwasny; Christian Menzel; Hellmut Samonigg; Michael Seifert; Guenther Gademann; Manfred Kaufmann; Johann Wolfgang Journal: Lancet Date: 2005 Aug 6-12 Impact factor: 79.321
Authors: Paul E Goss; James N Ingle; Silvana Martino; Nicholas J Robert; Hyman B Muss; Martine J Piccart; Monica Castiglione; Dongsheng Tu; Lois E Shepherd; Kathleen I Pritchard; Robert B Livingston; Nancy E Davidson; Larry Norton; Edith A Perez; Jeffrey S Abrams; David A Cameron; Michael J Palmer; Joseph L Pater Journal: J Natl Cancer Inst Date: 2005-09-07 Impact factor: 13.506
Authors: E Bajetta; N Zilembo; M Dowsett; L Guillevin; A Di Leo; L Celio; A Martinetti; A Marchianò; P Pozzi; S Stani; E Bichisao Journal: Eur J Cancer Date: 1999-02 Impact factor: 9.162
Authors: Eric P Winer; Clifford Hudis; Harold J Burstein; Antonio C Wolff; Kathleen I Pritchard; James N Ingle; Rowan T Chlebowski; Richard Gelber; Stephan B Edge; Julie Gralow; Melody A Cobleigh; Eleftherios P Mamounas; Lori J Goldstein; Timothy J Whelan; Trevor J Powles; John Bryant; Cheryl Perkins; Judy Perotti; Susan Braun; Amy S Langer; George P Browman; Mark R Somerfield Journal: J Clin Oncol Date: 2004-11-15 Impact factor: 44.544
Authors: Hubert W Vesper; Julianne C Botelho; Meghan L Vidal; Yasamin Rahmani; Linda M Thienpont; Samuel P Caudill Journal: Steroids Date: 2014-01-06 Impact factor: 2.668
Authors: James N Ingle; Aman U Buzdar; Daniel J Schaid; Matthew P Goetz; Anthony Batzler; Mark E Robson; Donald W Northfelt; Janet E Olson; Edith A Perez; Zeruesenay Desta; Randy A Weintraub; Clark V Williard; David A Flockhart; Richard M Weinshilboum Journal: Cancer Res Date: 2010-03-30 Impact factor: 12.701
Authors: James N Ingle; Krishna R Kalari; Aman U Buzdar; Mark E Robson; Matthew P Goetz; Zeruesenay Desta; Poulami Barman; Tanda T Dudenkov; Donald W Northfelt; Edith A Perez; David A Flockhart; Clark V Williard; Liewei Wang; Richard M Weinshilboum Journal: Steroids Date: 2014-08-24 Impact factor: 2.668